Defibrotide lowers rates of veno-occlusive disease after transplant

02/24/2012 | DoctorsLounge.com

Defibrotide prophylaxis can reduce cases of hepatic veno-occlusive disease among patients younger than 18 undergoing hematopoietic stem cell transplantation, German researchers found. The study in The Lancet journal showed that 12% of patients who received the drug developed veno-occlusive disease 30 days after transplantation, compared with 20% in the control group.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD